Pharma-Bio Serv, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PBSV research report →
Price Chart
About the company
Pharma-Bio Serv, Inc. functions as a specialized consulting firm, providing services focused on regulatory compliance and the transfer of technology. The company offers its compliance expertise to a diverse range of clients, including those in the pharmaceutical, chemical, biotechnology, medical device, cosmetic, and food industries, as well as related product companies.
- CEO
- Victor Sanchez
- IPO
- 2007
- Employees
- 55
- HQ
- Dorado, PR, PR
Get TickerSpark's AI analysis on PBSV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.99M
- P/E
- -1.34
- Fwd P/E
- 12.00
- PEG
- 0.18
- P/S
- 1.16
- P/B
- 0.00
- EV/EBITDA
- -390.57
- Div Yield
- 15.63%
- Gross Margin
- 32.32%
- Op Margin
- -1.63%
- Net Margin
- -147.13%
- ROE
- -0.27%
- ROIC
- -0.00%
Latest fiscal year · YoY change
- Revenue
- $9.00M-5.3%
- Gross Profit
- $2.91M+15.7%
- Op Income
- $-637,662
- Net Income
- $-100,463+87.1%
- EPS
- $-0.00+87.0%
- OCF Growth
- +62.1%
- FCF Growth
- +69.5%
- 52W High
- $0.70
- 52W Low
- $0.32
- 50D MA
- $0.49
- 200D MA
- $0.52
- Beta
- 0.73
- RSI (14)
- 51
- Avg Volume
- 2.73K
No earnings-call transcripts are available for PBSV yet.
- Free Float
- 35.3%
- Shares Outstanding
- 22.90M
- Float Shares
- 8.07M
Buy/sell ratio 1.40. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 9, 26 | SPINDEL HOWARD | other | 42,504 |
| Jan 10, 26 | MICHEL KIRK WHEELER | other | 20,000 |
| Jan 10, 26 | Perlysky Dov | other | 20,000 |
| Jan 10, 26 | SPINDEL HOWARD | other | 20,000 |
| Jan 10, 26 | WIESEN IRVING L | other | 20,000 |
| Jan 10, 25 | MICHEL KIRK WHEELER | other | 20,000 |
| Jan 10, 25 | Perlysky Dov | other | 20,000 |
| Jan 10, 25 | SPINDEL HOWARD | other | 20,000 |
| Jan 10, 25 | WIESEN IRVING L | other | 20,000 |
| Jan 10, 24 | Perlysky Dov | other | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PBSV coverage
Recent articles, reports, and earnings notes.
No research on PBSV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PBSV report →Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2026
accessnewswire.com · Sep 14
Pharma-Bio Serv (OTCMKTS:PBSV) Share Price Crosses Below 200 Day Moving Average – Should You Sell?
defenseworld.net · Aug 20
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2026
accessnewswire.com · Jun 15
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2026
accessnewswire.com · Mar 17
Pharma-Bio Serv Announces Full Year Results and Special Dividend
accessnewswire.com · Jan 29
Analyzing Pharma-Bio Serv (OTCMKTS:PBSV) and ATIF (NASDAQ:ZBAI)
defenseworld.net · Jan 7
ATIF (NASDAQ:ZBAI) and Pharma-Bio Serv (OTCMKTS:PBSV) Financial Analysis
defenseworld.net · Jan 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.